Published in PLoS One on May 02, 2014
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Cancer Res (2015) 0.88
Neural Regulation of Pancreatic Cancer: A Novel Target for Intervention. Cancers (Basel) (2015) 0.80
The potential impact of mouse model selection in preclinical evaluation of cancer immunotherapy. Oncoimmunology (2014) 0.76
Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma. Hum Vaccin Immunother (2015) 0.75
Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol (2007) 3.03
Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev (1999) 2.83
Development of TLR9 agonists for cancer therapy. J Clin Invest (2007) 2.64
Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer (2011) 2.42
Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer (2004) 2.20
Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol (2011) 2.18
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov (2013) 1.93
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.71
Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer (1992) 1.50
Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol (2013) 1.47
Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer. PLoS One (2013) 1.42
Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data. Anticancer Res (1993) 1.22
Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Mol Ther (2013) 1.20
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol (2010) 1.20
Immunotherapy of cancer with 4-1BB. Mol Cancer Ther (2012) 1.19
Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res (2010) 1.19
CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther (2008) 1.14
A murine renal cell carcinoma. J Natl Cancer Inst (1973) 1.09
Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res (2010) 1.08
Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS One (2009) 1.07
Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol Immunother (2011) 1.03
Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS One (2012) 1.00
Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur J Immunol (2005) 0.98
Antitumor activity mediated by CpG: the route of administration is critical. J Immunother (2011) 0.96
CpG plus radiotherapy: a review of preclinical works leading to clinical trial. Front Oncol (2012) 0.95
Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother (2011) 0.95
Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice. Clin Cancer Res (2009) 0.95
Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. J Transl Med (2010) 0.94
Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer. Target Oncol (2013) 0.92
Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects. World J Gastroenterol (2013) 0.91
Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. Br J Cancer (2013) 0.89
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin Pharmacol (2013) 0.89
Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2. Clin Cancer Res (2007) 0.88
Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach. PLoS One (2013) 0.87
Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites. Cancer Lett (2012) 0.86
Modulation of Doxorubicin sensitivity and level of p-glycoprotein expression in human colon-carcinoma cells by ectopic and orthotopic environments in nude-mice. Int J Oncol (1993) 0.85
The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Ther (2002) 0.84
Preclinical models in radiation oncology. Radiat Oncol (2012) 0.82
Experimental study on ultrasound-guided intratumoral injection of "Star-99" in treatment of hepatocellular carcinoma of nude mice. World J Gastroenterol (2003) 0.80